+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07155174

Evaluating ABBV-706 with Atezolizumab versus Standard Care for First-Line Treatment of Extensive Stage Small Cell Lung Cancer

Led by AbbVie · Updated on 2026-10-27

180

Participants Needed

70

Research Sites

126 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial focuses on adults with extensive stage small cell lung cancer ES-SCLC, a fast-growing cancer that often spreads early to other parts of the body including lymph nodes, liver, bones, adrenal glands, and brain. The study aims to evaluate the safety, optimal dose, and impact on disease activity of the investigational drug ABBV-706 given with atezolizumab, compared to the standard of care SOC treatment which includes etoposide, carboplatin, atezolizumab, and optional lurbinectedin. This is a phase 2 randomized study involving about 180 participants worldwide. Participants will be assigned to one of several groups receiving either ABBV-706 at one of two doses combined with atezolizumab or the SOC treatment. All treatments are given intravenously. The study includes an initial safety lead-in phase followed by an expansion phase to determine the best ABBV-706 dose. Treatment continues until the optimal dose is established or as long as needed, with the total study duration lasting up to approximately 69.5 months. Throughout the study, participants will have regular visits at medical facilities for monitoring. These visits include medical assessments, blood tests, questionnaires, and scans to track safety and disease progression. Researchers will measure adverse events and progression-free survival up to around 24 months, with additional outcomes such as response rates and overall survival monitored for up to 28 months. Safety and dose effects will be followed closely for the full study period.

CONDITIONS

Brief Title

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here